Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Immune function relies on an appropriate balance of the lymphoid and myeloid responses. In the case of neoplasia, this balance is readily perturbed by the dramatic expansion of immature or dysfunctional myeloid cells accompanied by a reciprocal decline in the quantity/quality of the lymphoid response. In this review, we seek to: (1) define the nature of the atypical myelopoiesis observed in cancer patients and the impact of this perturbation on clinical outcomes; (2) examine the potential mechanisms underlying these clinical manifestations; and (3) explore potential strategies to restore normal myeloid cell differentiation to improve activation of the host antitumor immune response. We posit that fundamental alterations in myeloid homeostasis triggered by the neoplastic process represent critical checkpoints that govern therapeutic efficacy, as well as offer novel cellular-based biomarkers for tracking changes in disease status or relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“Additionally, several factors produced by MDSCs such as IL-10 and IL-6 have been shown to drive the production of T regulatory (Treg) cells [3].”
BackgroundCouzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
The IRF Family Transcription Factors in Immunity and Oncogenesis
Tamura, T., Yanai, H., Savitsky, D., & Taniguchi, T. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090400 · Cited by 1,259
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947
Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793 · cited 1×
“HLA-DRlow/−CD14+ [46, 48] Hepatocellular carcinoma Linlow/−HLA-DR−CD33+ [49, 64] Renal cell carcinoma, melanoma, hepatocellular carcinoma CD11b+HLA-DR−CD33+CD14− [51] Esophageal cancer SSChighLin−CD11b+HLA-DRlowCD14−CD15+CD33+ [52]Gastric cancer Lin−/lowCD11b+HLA-DR−CD14−CD15−CD33+CD13+CD 39+CD66b− [55] Colorectal can…”
BackgroundHoltschke, T., Löhler, J., Kanno, Y., Fehr, T., Giese, N., Rosenbauer, F., Lou, J., Knobeloch, K.-P., Gabriele, L., Waring, J. F., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81348-3 · Cited by 644 · cited 1×
“Such IRF-8−/− mice also show a substantial reduction in the number of mature macrophages [79], with the remaining macrophages being functionally impaired [83, 84].”
BackgroundWu, P., Wu, D., Ni, C., Ye, J., Chen, W., Hu, G., Wang, Z., Wang, C., Zhang, Z., Xia, W., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.013 · Cited by 608
Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., & Clements, V. K. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.011 · Cited by 583
Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1508-5 · Cited by 560
Cited by
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
The lung microenvironment: an important regulator of tumour growth and metastasis
Altorki, N. K., Markowitz, G. J., Gao, D., Port, J. L., Saxena, A., Stiles, B., McGraw, T., & Mittal, V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0081-9 · Cited by 1,150
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
Condamine, T., Dominguez, G. A., Youn, J.-I., Kossenkov, A. V., Mony, S., Alicea-Torres, K., Tcyganov, E., Hashimoto, A., Nefedova, Y., Lin, C., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf8943 · Cited by 789
Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653
Embracing cancer complexity: Hallmarks of systemic disease
Swanton, C., Bernard, E., Abbosh, C., André, F., Auwerx, J., Balmain, A., Bar-Sagi, D., Bernards, R., Bullman, S., DeGregori, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.009 · Cited by 540
Ostrand-Rosenberg, S., & Fenselau, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701019 · Cited by 509
“As investigators became more aware of MDSC and tested for them in both cancer patients and mice with tumors, MDSC were increasingly recognized as a major spoiler of antitumor immunity because they accumulate in virtually all individuals with cancer (13, 14).”
BackgroundFacilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W., Wang, J., Wang, X., & Fu, Y.-X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.004 · Cited by 472
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Myeloid Cell-Derived Arginase in Cancer Immune Response
Grzywa, T. M., Sosnowska, A., Matryba, P., Rydzynska, Z., Jasinski, M., Nowis, D., & Golab, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00938 · Cited by 424
Transcriptional regulation of myeloid-derived suppressor cells
Condamine, T., Mastio, J., & Gabrilovich, D. I. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.4ri0515-204r · Cited by 372
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
Delivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis
Li, P., Lu, M., Shi, J., Gong, Z., Hua, L., Li, Q., Lim, B., Zhang, X. H.-F., Chen, X., Li, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0783-5 · Cited by 253
Dominguez, G. A., Condamine, T., Mony, S., Hashimoto, A., Wang, F., Liu, Q., Forero, A., Bendell, J., Witt, R., Hockstein, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1784 · Cited by 187
Metadata
- Authors
- Messmer, M. N., Netherby, C. S., Banik, D., & Abrams, S. I.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2014-11-29
- Volume
- 64
- Issue
- 1
- Pages
- 1-13
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2040071669
- Cited by
- 120
- References
- 25
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.